Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion. Wir bitten um Ihr Verständnis.
Welcome to the Division of Molecular Pathology, a research laboratory devoted to translational research, connecting basic moledular biology with medical sciences.
The research of the Kirfel lab focuses on the control of transcriptional regulation, particularly on cofactors and chromatin modifying enzymes, with emphasis on their roles in cancer. To address these areas, we utilize state-of-the-art molecular, cellular and biochemical techniques in combination with next generation technologies such as ChIP-seq and RNA-seq.
In addition, we evaluate new strategies for molecular pathological diagnostics in order to implement the most suitable methods into routine diagnostics.
The lab is interested in several aspects of cancer research:
Poject: Histone modifying enzymes
The genetic abnormalities that drive tumorigenesis are usually coupled with epigenetic alterations, such as DNA methylation and aberrant histone modifications, which may help oncogenic drivers accelerate cancer progression, metastasis, and therapy resistance. Histone methylation has been shown to be a key player in the regulation of gene expression and genetic stability, and not surprisingly, dysregulation of this highly conserved process occurs in various cancers. The recent discovery of histone demethylases and their role in the regulation of posttranslational modifications of chromatin have greatly contributed to our understanding of epigenetics in tumorigenesis and have provided potential additional therapeutics. We are interested in understanding the functions of histone demethylases in cancer and the potential therapeutic value to target histone demethylases in cancer.
Project: Mediator complex
We are also investigating the role of Mediator complex subunits in lung cancer initiation, progression and metastasis. The Mediator complex is the central integrator of transcription an influences different signaling pathways, therefor it is not surprising that aberrant expression of activity of Mediator complex subunits are linked to activation of oncogenic signaling pathways that lead to cancer progression and metastasis. Our aim is to investigate whether dysregulation in non-small-cell lung carcinoma (NSCLC) depend on aberrant activity of the Mediator complex and whether its subunits can be used as drug targets in metastatic NSCLC.
Project: Cancer diagnostics
Several cancer genome alterations are important in guiding molecularly informed therapy decision. Therefore, sensitive analytical methods are needed to ensure accurate molecular diagnosis and therapeutic patient stratification. We work on developing sensitive methods for the detection of somatic alteration in clinical cancer specimens.